• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Entos Pharmaceuticals announces research, development and collaboration agreement

Bioengineer by Bioengineer
October 2, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: (c) Entos Pharmaceuticals

EDMONTON, Alberta, October 2, 2019 — Entos Pharmaceuticals Inc. (“Entos” or the “Company”), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement (“Agreement”) with a clinical stage biopharmaceutical company (“Partner”) focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.

Under the terms of the agreement, the Partner has the option to exclusively license candidates developed under the Agreement from Entos for further development and commercialization. In return, Entos receives research funding and is eligible for option exercise fees, research, development, regulatory, and sales milestone payments of up to US$109 million. In addition, the Partner will pay Entos undisclosed royalties on sales of products resulting from the collaboration.

“This marks our second major collaboration for the Fusogenix technology and represents further validation of our non-viral repeat dosing nucleic acid delivery platform,” said Dr. John Lewis, President & CEO of Entos. “We are excited to be working with our new partner to develop new clinical immunotherapy candidates.”

Deloitte Corporate Finance Inc. acted as exclusive financial advisor and Norton Rose Fulbright Canada LLP acted as legal counsel to Entos on the transaction.

###

About Entos Pharmaceuticals, Inc.

Entos is focused on the development of next-generation nucleic acid-based therapies using its proprietary Fusogenix drug delivery system. Fusogenix uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi, and CRISPR. For more information, visit http://www.entospharma.com

For more information regarding this press release, contact:

Entos Contact

John D. Lewis, Ph.D.

President & CEO, Entos Pharmaceuticals, Inc.

Phone: (780) 862-7445

Email: john.lewis@entospharma.com

Media Contact
John D. Lewis
john.lewis@entospharma.com

Tags: Biomedical/Environmental/Chemical EngineeringBiotechnologyCollaborationImmunology/Allergies/AsthmaMedicine/HealthNanotechnology/MicromachinesPharmaceutical SciencePharmaceutical SciencesResearch/Development
Share12Tweet8Share2ShareShareShare2

Related Posts

Global Breast Cancer Drug Trials Surged Fivefold While Reporting Gaps Persisted

Global Breast Cancer Drug Trials Surged Fivefold While Reporting Gaps Persisted

November 20, 2026
Methodological Issues Weaken Evidence on Failed Spinal Anesthesia Predictors and Incidence

Methodological Issues Weaken Evidence on Failed Spinal Anesthesia Predictors and Incidence

November 20, 2026

Police Study Associates Dark Humor With Greater Psychological Distress and Pathology

November 20, 2026

Peer-Delivered Future Thinking Intervention Shows Promise in Substance Use Reentry Trial

November 20, 2026
Please login to join discussion

POPULAR NEWS

  • Biostable Insect Kinin Mimetics Deter Mosquito Blood and Sugar Feeding

    Biostable Insect Kinin Mimetics Deter Mosquito Blood and Sugar Feeding

    29 shares
    Share 12 Tweet 7
  • Phenomenology offers ethical framework for South Asian end-of-life care

    29 shares
    Share 12 Tweet 7
  • Multi-Solver Finite Element Framework Accurately Predicts Freeway Tunnel Stability

    29 shares
    Share 12 Tweet 7
  • Creep Model Simulates Sustained Deformation in South China Sea Hydrate Sediments

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Framework Improves Reasoning Efficiency in Sparse Temporal Knowledge Graphs

Global Breast Cancer Drug Trials Surged Fivefold While Reporting Gaps Persisted

Electroless Multimetal Alloy Deposition Enhances Graphene Oxide Thermal Stability and Modifies Structure

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.